BiotechTube

Bromocriptine Mesilate + Placebos

Phase 1/2Completed
0 watching 0 views this week⚡ Active
40
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Familial Alzheimer Disease (FAD)

Conditions

Familial Alzheimer Disease (FAD), PSEN1 Mutation

Trial Timeline

Jun 5, 2020 → Nov 24, 2021

NCT ID
NCT04413344

About Bromocriptine Mesilate + Placebos

Bromocriptine Mesilate + Placebos is a phase 1/2 stage product being developed by Towa Pharmaceutical for Familial Alzheimer Disease (FAD). The current trial status is completed. This product is registered under clinical trial identifier NCT04413344. Target conditions include Familial Alzheimer Disease (FAD), PSEN1 Mutation.

Hype Score Breakdown

Clinical
13
Activity
8
Company
9
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04413344Phase 1/2Completed

Competing Products

20 competing products in Familial Alzheimer Disease (FAD)

See all competitors
ProductCompanyStageHype Score
SHR-1209Jiangsu Hengrui MedicinePhase 2
52
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
77
Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
77
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calciumAstraZenecaPhase 3
77
Rosuvastatin + PlaceboAstraZenecaPhase 3
77
Rosuvastatin 20mgAstraZenecaPhase 3
77
AZD0780 + PlaceboAstraZenecaPhase 3
77
Anacetrapib + Placebo for anacetrapibMerckPhase 3
77
Statins and EzetimibeMerckPre-clinical
23
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placeboMerckPhase 3
77
MK-0524A + MK-0524AMerckPhase 1
33
Enlicitide Decanoate + PlaceboMerckPhase 2/3
65
Inclisiran + PlaceboNovartisPhase 3
77
DFV890NovartisPhase 2
52
CanakinumabNovartisPhase 2
52
Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
77
LCQ908 + PlaceboNovartisPhase 3
77
InclisiranNovartisPhase 3
77
Inclisiran + PlaceboNovartisPhase 3
77
FluvastatinNovartisPhase 3
77